Breast Cancer
Seprase (FAP) stands as a critical therapeutic target in breast cancer because of its overexpression in cancer-associated fibroblasts (CAFs) in the tumor microenvironment. The progression of tumors, metastasis, and resistance to therapies are driven by FAP through remodeling of the extracellular matrix, and suppression of the immune response. Alfa Cytology provides a complete seprase (FAP)-targeted end-to-end service with advanced technologies to address unmet needs.
Introduction to Breast Cancer
Over 80% of breast cancers express seprase (FAP), particularly the more aggressive triple-negative subtype and in metastatic tumours. Its enzymatic activity drives collagen degradation, angiogenesis, and immunosuppression, thereby exhibiting potentials for dual diagnosis and therapy. In recent studies, seprase (FAP)-targeting therapies have confirmed effectiveness in tumor growth inhibition and enhancement of radiotherapy efficacy.
Fig. 1 Immunohistochemistry of Fibroblast Activation Protein (FAP) expression across different tumor types and subtypes. (Dziadek, S., et al. 2023)
For instance, seprase (FAP)-targeting biomimetic nanosystem loaded with seprase (FAP)-activated CAFs has been developed, targeting and restoring activated CAFs into a quiescent state and thus improving upon the tumor immune microenvironment and anti-tumor immunity.
Seprase (FAP)-Targeted Drug Development for Breast Cancer
| Name | Indication | Company | Phase |
| PNT6555 | Triple-Negative Breast Cancer | Perspective Therapeutics | Preclinical |
| CLR 131 | HER2+ Breast Cancer | Cellectar Biosciences | Phase I |
| FAPI-04 | Metastatic Breast Cancer | Heidelberg Univ. | Phase II |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Alfa Cytology is focused on developing drugs against seprase (FAP) targets for breast cancer using integrated platforms that combine target validation, molecular design, and preclinical evaluation. The multi-domain team rapidly translates a concept into viable candidates for the clinic.
Tailored Therapy Development for Breast Cancer Subtypes
| Multiple Subtypes | Services |
| Triple-Negative Breast Cancer (TNBC) | FAP-CAR NK Cell & Nanomedicine |
| HR+/HER2- Breast Cancer | FAP-Activated Prodrugs & Radiotherapy |
| HER2+ Resistant Breast Cancer | Dual-Targeting FAP/HER2 ADCs |
| Bone Metastases Breast Cancer | FAP-Targeted Radioligand Therapy (RLT) |
Alfa Cytology supplies you with end-to-end seprase (FAP) solutions to enable breast cancer drug discovery. The actionable results will span everything from molecular design to preclinical validation. To find out more about how our expertise can assist in speedily advancing your project, contact our team today.
Reference
- Dziadek, S., et al. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies. Frontiers in immunology. 2024, 15: 1352615.
For research use only.